Abstract
Preeclampsia is a life-threatening syndrome developing in pregnancy, the main features of which are hypertension and proteinuria. Frequency of preeclampsia has no tendency to decrease (3-7%), and it still takes the leading position in the structure of maternal mortality and morbidity worldwide. In this review, we present the “fibrotic concept” of the etiology and pathogenesis of preeclampsia, which involves system consisting of Na/K-ATPase and its endogenous ligands including marinobufagenin induced Fli1 inhibition. New therapy of preeclampsia includes modulation of the Na/K-ATPase system by immunoneutralization of marinobufagenin.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
